Cancel
Dechra Pharmaceuticals
Dechra Pharmaceuticals Employees
9 people indexed:
-
Giles Coley
Dechra Veterinary Products International Group Director
f72z0.tz963@qwbxk0.b3x Sign up to see emailff787.qt183@66tzwp.136 Sign up to see email -
fjf.8k8v@99w2k8.qv2 Sign up to see email
-
u6y45.t6zbq@6937gn.5u6 Sign up to see email
-
jns3.55if64@i4760s.6pj Sign up to see email
-
9u18v2q.t675@6uup1w.qtf Sign up to see email
-
9vjv.ub12b8@5g4168.gbx Sign up to see email
-
5fzzyu.kzvjpv@x6k91k.6v2 Sign up to see email
-
y2qb34f.5xllx@ylwg65.vng Sign up to see email
-
9y7t.k0zt7t5i@77g6g2.vqi Sign up to see email
Dechra Pharmaceuticals Company Information
Dechra Pharmaceuticals is a company dedicated to the veterinary pharmaceuticals and related products industry. It focuses on the development, manufacture, marketing, and sales of high-quality products exclusively for veterinarians worldwide. The company has a significant global footprint, with its products available in 88 countries, and it operates 8 manufacturing sites. Dechra employs 2,457 people globally and has established sales and marketing organizations in 26 countries. The company’s product portfolio includes a variety of pharmaceuticals and related items for companion animals, equine, and food-producing animals. Additionally, Dechra is committed to supporting the veterinary community through educational and training programs, and it provides technical support and pharmacovigilance services through helplines in every country where it operates. On the environmental front, Dechra is focused on sustainability, aiming for zero to landfill by 2025 and net zero emissions by 2050. It has set science-based targets for reducing greenhouse gas emissions, which have been approved by the Science Based Targets initiative (SBTi). Specifically, Dechra aims to reduce its absolute Scope 1 and 2 greenhouse gas emissions by 42% and Scope 3 emissions by 51.6% per GBP value added by 2030, using 2021 as the base year.
Report inaccurate information
Report inaccurate information
